title: Efficient enhancement of priming effect by intermittent treatment with interferon.
abstract: To improve the efficacy of interferon (IFN) therapy for chronic hepatitis C, we proposed a therapy with twice-a-day injection of IFNbeta as the induction. To assess its biological enhancement, we compared antiviral activities in vitro using intermittent treatment schedules simulating the clinical condition. FL cells were treated with IFNbeta twice in 12 h interval (Single treatment, 1000 and 0 IU/ml; Double treatment, 500 IU/ml each) and challenged with Sindbis virus. Antiviral activities were determined with 50% cytopathic effect. Activities and mRNA expressions of 2'5'oligoadenylate synthetase (2'5'AS) were also examined. Single treatment showed its peak activity at 9 h, while Double treatment was at 3 h after the second treatment. Double treatment had a significantly higher peak activity. The up-regulated activities of 2'5'AS lasted much longer with Double treatment. The present findings demonstrated Double treatment could induce efficient biological enhancement, which is thought based on the priming effect.
authors.affiliation: First Department of Internal Medicine, Okayama University Medical School, Okayama, 700-8558, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Ikeda
authors.forename: H
authors.initials: H
authors.lastname: Shimomura
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: H
authors.initials: H
authors.lastname: Tsuji
authors.forename: S
authors.initials: S
authors.lastname: Fukioka
authors.forename: M
authors.initials: M
authors.lastname: Itoh
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000235:genetics* / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology*; D007700:Kinetics; D008954:Models, Biological; D010920:Placenta; D011247:Pregnancy; D012333:RNA, Messenger / Q000235:genetics; D012845:Sindbis Virus / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D012333:RNA, Messenger; D016899:Interferon-beta; D015088:2',5'-Oligoadenylate Synthetase